Chiome Bioscience 

Chiome Bioscience Inc. engages in the research and development of drug discovery technology platforms worldwide. The company operates through two segments, Drug Discovery and Development Business and Drug Discovery Support Business. It offers ADLib System, a monoclonal antibody generating system for drug discovery and development. The company also provides protein expression and purification services; stable cell line generation services for recombinant protein and antibody production; and antibody generation services using the ADLib system or B cell cloning techniques. Its product pipeline includes ADCT-701, an anti-dlk1 antibody for treating liver cancer; CBA-1205, an afucosylated anti-dlk1 antibody for liver cancer, lung cancer, neuroblastoma, etc.; CBA-1535, an anti 5T4/WAIF1 antibody for malignant mesothelioma, small cell lung cancer, non-small cell lung cancer, breast cancer (TNBC), etc.; LIV-2008/2008b, an anti-TROP-2 antibody for the treatment of TNBC, lung cancer, colorectal cancer, etc.; and BMAA, an anti-semphorin3a antibody for treating central, immune/ inflammatory diseases, neurological disorder, and ophthalmic diseases. The company serves universities, research institutions, and pharmaceutical companies. It has a collaborative research agreement with Mologic Ltd. for antibody discovery and development for use in advanced diagnostic tests. Chiome Bioscience Inc. was incorporated in 2005 and is headquartered in Tokyo, Japan.